Abstract
Multiple SARS-CoV-2 variants that possess mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. While the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.529) spike appear to diminish the efficacy of pre-existing immunity. Using pseudoparticles expressing the spike of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in naturally infected and in mRNA-vaccinated individuals. We observed that while boosting increases the magnitude of the antibody response to wildtype (D614), Beta, Delta and Omicron variants, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses while responses were relatively reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.
One Sentence Summary Diminished efficacy of pre-existing immunity to highly mutated SARS-CoV-2 variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Conrad Prebys Foundation 204 (RHS, GST) Fast Grants (TTW) CEND COVID Catalyst Fund (TTW) Crown Foundation Sunshine Foundation Marino Family Foundation National Institutes of Health U19AI111825 (TTW) National Institutes of Health U54CA260517 (TTW) National Institutes of Health R01AI137365 (SV) National Institutes of Health R03AI146632 (SV) National Institutes of Health 75N93019C00076 (RHS) BARDA ASPR-20-01495 (MBF) Health and Human Services HHSN272201400008C / 0258-0686-4609 (MBF) Support for Stanford biobanking was supported in part by support from the Quattrone Family and from Fast Grants
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by Institutional Review Board of Stanford University (IRB-556719 and IRB-8629) and the University of California at San Francisco Institutional Review Board (20-32077).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
